Vireo Growth Inc · CSE:VREO
Vireo Growth — Vireo Health — FY2018 Earnings Presentation
17 slides from Vireo Growth's earnings presentation, Apr 30, 2019
Slide 1: Fourth Quarter and FY18 Results
Fourth Quarter and FY18 Results April 30, 2019
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This document includes information, statements, beliefs and opinions which are forward- looking, and which reflect current estimates, expectations and projections about future events, referred to herein and which constitute “forward-l
Slide 3: Today's Presenters
Today’s Presenters Kyle Kingsley, M.D. Founder & Chief Executive Officer Dial-in & Webcast Details: Dial-ins: 866-211-3165 (Toll-Free) B647-689-6580 (International) .BID 4176936 Amber Shimpa Chief Financial Officer Webcast Link: https://investors.vireohealth.com/events- and-presentations/ Sam Gibbon
Slide 4: Our Mission
Our Mission “We are building the cannabis company of the future by bringing the best of science, medicine and engineering to the cannabis industry.” - Kyle Kingsley, M.D. Founder & CEO FY18 Results Conference Call || 4
Slide 5: Fourth Quarter and FY18 Business Highlights
Fourth Quarter and FY18 Business Highlights • Vireo generated revenue in three states in fiscal year 2018: Minnesota, New York, and Pennsylvania. • Fourth quarter revenue increased 72 percent year-over- year to $5.6 million. Full year 2018 revenue increased approximately 70 percent year-over-year to
Slide 6: Vireo's Current Footprint
Vireo’s Current Footprint: MN MA NY RI PA NV OH CA MD AZ Current Footprint NM Binding Purchase & Sale Agreement(1) Subject to pending transactions Hemp assets Puerto Rico (1) Vireo expects this transaction to close during the second-quarter of 2019, subject to customary conditions of closing FY18 Re
Slide 7: Green Goods Dispensary Concept Launching in Q2
Green Goods™ Dispensary Concept Launching in Q2 • Vireo’s retail outlets are being transformed and rebranded to Green Goods™ dispensaries. The first locations are expected to begin opening in Pennsylvania during the second quarter. • Stores will feature an inviting health and wellness environment, f
Slide 8: FY18 Results Conference Call || 8
FY18 Results Conference Call || 8
Slide 9: Intellectual Property Portfolio
Intellectual Property Portfolio Short Term Monetization Long-Term Applications Cannabis Moist Snuff Composition Harm Reduction Additive for Tobacco Products Multi-Channel Vaporizer Method for Treating Non-Cannabinoid Negative Control Antidepressant Withdrawal Formulations (Placebo) Syndrome Propriet
Slide 10: Key Fourth Quarter and FY18 Financial Metrics
Key Fourth Quarter and FY18 Financial Metrics Three Months Ended Twelve Months Ended December 31, December 31, $ in millions, except per share data 2018 2017 Variance 2018 2017 Variance Revenue $5.6 $3.3 $2.4 $18.5 $10.9 $7.6 Gross Profit (After Fair Value Adjustments) $5.4 $1.2 $4.2 $16.8 $6.4 $10.
Slide 11: Fourth Quarter 2018 Performance
Fourth Quarter 2018 Performance Revenue Bridge (4Q’17 to 4Q’18) • Total revenue for the fourth quarter of 2018 increased 72 percent year-over-year to $5.6 $ in millions million. • Growth was driven by increased patient counts and demand in Minnesota and New York, as well as the beginning of wholesal
Slide 12: Fiscal Year 2018 Performance
Fiscal Year 2018 Performance Revenue Bridge (FY’17 to FY’18) • Total revenue for fiscal 2018 increased 70 percent year-over-year to $18.5 million. $ in millions • Growth was driven by increased patient counts and demand in Minnesota and New York, as well as the beginning of wholesale revenue generat
Slide 13: Fiscal Year 2019 Development Plans
Fiscal Year 2019 Development Plans During fiscal year 2019, Vireo expects to: • Launch Green Goods™ dispensaries in Pennsylvania and expand its retail footprint in New Mexico • Increase cultivation and processing capacity in Arizona, Minnesota, New Mexico and New York • Begin building new facilities
Slide 14: Appendix
Slide 15: Reconciliation of IFRS to Non-IFRS Financial Measures
Reconciliation of IFRS to Non-IFRS Financial Measures Three Months Ended Twelve Months Ended December 31, December 31, 2018 2017 2018 2017 Net income (loss) (IFRS) $ (1,182,621) $ 273,098 $ (3,077,353) $ (430,689) Transaction costs 386,882 - 448,480 - Share-based compensation 572,869 - 2,072,706 - N
Slide 16: Consolidated Statements of Loss and Comprehensive Loss
Consolidated Statements of Loss Vireo Health, Inc. Consolidated Statements of Loss and Comprehensive Loss and Comprehensive Loss For the Years Ended December 31, 2018 and 2017 Year Ended December 31, Year Ended December 31, (Expressed in United States Dollars) 2018 2017 REVENUE $ 18,459,069 $ 10,867
Slide 17: Consolidated Statement of Financial Position
Vireo Health, Inc. Consolidated Statement of Financial Position Consolidated Statement of Financial Position For the Years Ended December 31, 2018 and 2017 December 31, December 31, (Expressed in United States Dollars) 2018 2017 ASSETS Current Assets Cash $ 9,624,110 $ 2,595,965 Receivables 1,671,25